


Anti-S1PR4 Recombinant Antibody Products

Anti-S1PR4 Products
-
- Species Reactivity: Human
- Type: Human IgG2
- Application: ELISA, WB
-
- Species Reactivity: Human
- Type: Human scFv
- Application: ELISA, WB
- Human Anti-S1PR4 Recombinant Antibody; Fab Fragment (TAB-383CT-F(E)) (TAB-383CT-F(E))
-
- Species Reactivity: Human
- Type: Human Fab
- Application: ELISA, WB
-
- Species Reactivity: Human
- Type: Mouse IgG1
- Application: WB, FC
-
- Species Reactivity: Human
- Target: S1PR4
- Host Animal: Human
- Application: ELISA, FC, Cell-uptake
Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
Creative Biolabs, drawing on extensive expertise in antibody engineering, presents an extensive range of recombinant anti-S1PR4 antibodies. Tailored for researchers worldwide, our carefully developed antibodies demonstrate outstanding specificity, affinity, and consistent quality across batches, enhancing your studies on the vital role of S1PR4 in immunology, inflammation, and more. Discover our varied offerings and propel your scientific advancements.
S1PR4: A Key Modulator of Immune Cell Function
S1PR4, or sphingosine-1-phosphate receptor 4, is a G protein-coupled receptor that binds the lipid signaling molecule sphingosine 1-phosphate (S1P) and plays a significant role in the immune system, particularly within lymphoid and hematopoietic tissues as well as the lungs. Upon activation by S1P, S1PR4 couples to Gi and G12/13 proteins, influencing various cellular processes such as cell shape, motility, and immune cell function, including activation, differentiation, and potentially trafficking. Recent research suggests S1PR4's involvement in modulating innate immune cell activation and cytokine production, impacting inflammatory responses and even tumor progression, making it a potential therapeutic target for immune-related diseases and cancer.
Alternative Names
Sphingosine-1-phosphate receptor 4; S1P receptor 4; EDG6; LPC1; S1P4; SLP4.
Background
The protein encoded by this gene is structurally similar to G protein-coupled receptors and is highly expressed in endothelial cells. It binds the ligand sphingosine-1-phosphate with high affinity and high specificity, and suggested to be involved in the processes that regulate the differentiation of endothelial cells. Activation of this receptor induces cell-cell adhesion. Alternative splicing results in multiple transcript variants.
G-protein coupled receptors
Membrane
Cell type enhanced (NK-cells, dendritic cells, T-cells, B-cells, monocytes)
Low immune cell specificity
Cell line enhanced (HDLM-2, HL-60, NB-4, REH, U-937)
G-protein coupled receptor, Receptor, Transducer
Anti-S1PR4 rAb Products
Creative Biolabs' cutting-edge recombinant anti-S1PR4 antibodies are engineered for superior performance in your research. Unlike traditional antibodies, our recombinant technology ensures unparalleled lot-to-lot consistency and eliminates batch variability, providing reliable and reproducible results. Benefit from high specificity, minimizing off-target binding and ensuring accurate target identification. Choose from a variety of formats and modifications tailored to diverse applications, empowering your studies with confidence and precision.
Table 1. Featured anti-S1PR4 recombinant antibody products at Creative Biolabs.
Cat. No. | Product Name | Target Species | Host Species | Applications |
ZG-0670F | Mouse Anti-S1PR4 Recombinant Antibody (clone 1) | Human | Mouse IgG1 | WB, FC |
TAB-383CT | Human Anti-S1PR4 Recombinant Antibody (TAB-383CT) | Human | Human IgG2 | ELISA, WB |
TAB-383CT-S(P) | Human Anti-S1PR4 Recombinant Antibody; scFv Fragment | Human | Human scFv | ELISA, WB |
Creative Quality Control
At Creative Biolabs, rigorous quality control is paramount. Each anti-S1PR4 recombinant antibody undergoes a comprehensive suite of tests, including ELISA, SDS-PAGE, and flow cytometry, to verify its identity, purity, and binding activity. We employ advanced techniques to ensure optimal performance and validate our antibodies across multiple applications. This commitment to quality guarantees that our products consistently meet the highest standards, delivering reliable and trustworthy results for your critical experiments.
Fig.1 WB analysis of anti-SIPR4 antibody
(Cat# ZG-0670F, Creative Biolabs).
Fig.2 IF analysis of anti-SIPR4 antibody
(Cat# ZG-0670F, Creative Biolabs).
Customer Reviews

Mouse Anti-S1PR4 Recombinant Antibody (clone 1) (ZG-0670F)

Human Anti-S1PR4 Recombinant Antibody (TAB-383CT) (TAB-383CT)

Mouse Anti-S1PR4 Recombinant Antibody (clone 1) (ZG-0670F)
rAb Production
The production of our recombinant anti-S1PR4 antibodies involves state-of-the-art facilities and optimized protocols. We utilize advanced recombinant techniques to ensure high yields and exceptional purity. Our experienced team carefully monitors each step, from gene synthesis to final product formulation, to maintain the highest quality standards.
Featured Anti-S1PR4 Recombinant Antibody Production Platforms
Fig.3 Milligram-scale anti-S1PR4 recombinant antibody production.
Fig.4 Gram-scale anti-S1PR4 recombinant antibody production.
rAb Modalities
Creative Biolabs provides high-quality, custom anti-S1PR4 recombinant antibodies that are precisely tailored to satisfy the various demands of researchers around the world.
Fig.5 Full-length anti-S1PR4 recombinant antibody production and modalities.
S1PR-Targeted Drug Information-1
Table 2. Public drug targeting S1PR.
Company | Research phase | Classification | Condition |
ALS Therapy Development Inst (ALS TDI) (ALS Therapy Development Institute) ALS Therapy Development Institute First Affiliated Hosp Fujian Med Univ Indiana University Mitsubishi Tanabe Pharma (Originator) Novartis Taito (Originator) |
Launched - 2010 | Prodrugs |
Amyotrophic lateral sclerosis Asthma Chronic inflammatory demyelinating polyneuropathy Immunosuppression Multiple sclerosis Multiple sclerosis, primary progressive Multiple sclerosis, relapsing-remitting Optic neuritis Polyneuropathy, demyelinating Renal Disorders Rett syndrome Schizophrenia Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) Transplant rejection Transplant rejection, kidney |
Lpath (Originator) Lpath Therapeutics (Lpath) Merck Serono Pfizer |
Phase II |
Cancer Immunotherapy Humanized Monoclonal Antibodies |
Cancer Cancer, kidney (renal cell carcinoma) Heart failure Retinal detachment Wet macular degeneration (exudative) |
VYNE Therapeutics (Originator) | Phase I/II |
Fixed-Dose Combinations Prodrugs |
Atopic dermatitis |
Institute of Materia Medica of Beijing (Originator) | Phase I | Prodrugs | Psoriasis |
Washington University (Originator) | Phase I |
Carbon-Radiolabeled Products Nuclear Imaging Agents |
Atherosclerosis Injury, vascular Multiple sclerosis Neurodegeneration Neuroinflammation |
Bristol-Myers Squibb (Originator) | Phase I | Prodrugs |
Autoimmune disease Rheumatoid arthritis |
Daiichi Sankyo (Originator) | Discontinued | Prodrugs |
Immunological Disorders Multiple sclerosis |
Washington University (Originator) | Preclinical |
Fluorine-Radiolabeled Products Nuclear Imaging Agents |
Neuroinflammation |
Capital Medical University (CMU) (Originator) Ocean University of China (Originator) |
Preclinical | Chemosensitizers | Cancer, colorectal |
Washington University (Originator) | Preclinical |
Fluorine-Radiolabeled Products Nuclear Imaging Agents |
Neurological Disorders |
Washington University (Originator) | Preclinical |
Fluorine-Radiolabeled Products Nuclear Imaging Agents |
Neurological Disorders |
(Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)
S1PR-Targeted Drug Information-2
Table 3. Drug targeting S1PR (under development).
Company | Research phase | Classification | Condition |
Autobahn Therapeutics (Originator) | Biological Testing | Prodrugs |
Adrenoleukodystrophy, X-linked Multiple sclerosis |
Autobahn Therapeutics (Originator) | Biological Testing | Prodrugs |
Adrenoleukodystrophy, X-linked Multiple sclerosis |
Novartis (Originator) | Biological Testing | Deuterated Compounds | Inflammation, lung |
Korea Institute of Science & Technology (Originator) | Biological Testing | Selenium Compounds | Multiple sclerosis |
Korea Institute of Science & Technology (Originator) | Biological Testing |
Prodrugs Selenium Compounds |
Multiple sclerosis |
Korea Institute of Science & Technology (Originator) | Biological Testing | Selenium Compounds | Multiple sclerosis |
Beijing Shenlantai Pharmaceutical Technology (Originator) | Biological Testing | Chemosensitizers | Cancer |
University of California (Originator) | Biological Testing |
Pegylated Drugs Prodrugs |
Cancer Multiple sclerosis |
Celgene | Biological Testing | Cocrystals |
Multiple sclerosis Psoriasis |
(Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)
Creative Biolabs is committed to providing researchers with the tools they need to advance scientific understanding. With our extensive experience and dedication to quality, we are confident that our anti-S1PR4 recombinant antibodies will be valuable assets in your research endeavors. For more information about our products and services, please don't hesitate to contact us.